Friday, February 29, 2008

Alkermes (NASDAQ:ALKS): Zyprexa delay very positive for ALKS - Baird

- Baird is out with a good call on Alkermes (NASDAQ:ALKS) after Eli Lilly (LLY) announced that it has received a Not Approvable Letter for Zyprexa Long-Acting Injection (LAI) for the treatment of schizophrenia.

This is very positive for ALKS, as it delays or possibly removes a potential threat to Risperdal Consta. FDA cited concern over the excessive sedation that was seen in approximately 1% of patients in clinical trials, and the agency needs more information to better understand the risk and underlying cause of these events.

Firm notes JNJ submitted an NDA for another potential competitor to Risperdal Consta, paliperidone palmitate, on 10/29/07. Given Invega's poor launch (less than 2% market share after one year), they do not think that paliperidone palmitate is a serious threat to Risperdal Consta. Notes that JNJ is committed to Risperdal Consta as evidenced by the heavy investment in Phase IV clinical trials for the product.

Reits Outperform and $24 tgt on ALKS saying they are buyers of the stock.

Notablecalls: The LLY news hit in pre-mkt yesterday, yet there was no reaction in ALKS. I think we will get one today.

Thursday, February 28, 2008

EnerNOC (NASDAQ:ENOC): Actionable Trading Call!

EnerNOC (NASDAQ:ENOC) got killed yesterday following weaker than expected results and there may be some more downside eary on as Jeffco is out downgrading their rating to Hold from Buy this morning (tgt goes to $18 from $54). Yet, we have some interesting defenses out as well, which indicate the stock may be a bounce candidate:

- JMP Securities is maintaining their Market Outperform rating while decreasing their price target from $50 to $35. EnerNOC's stock took at 36% haircut yesterday and is now down 67% year to date. While all metrics during the quarter pointed in the right direction -- higher than expected MW under management in 4Q07, above average MW additions QTD, and higher gross margins -- the company took a beating from investors. Higher than expected operating costs drove EPS lower than analysts' expectations, resulting in a miss. In addition, management's comments indicating that they plan to grow the engineering bench by 40-50% by the end of the year added more fuel to the fire. Lastly, management's comments indicating that the average price per MW could be down slightly in 2008
probably helped send investors running.

They see this as a unique buying opportunity noting that with the demand response market growing rapidly and average 5-year contract ROIs north of 20% in EnerNOC's business, they believe management's objective to rapidly expand sales while incurring higher upfront costs is warranted.

- Morgan Stanley while maintaining their Underweight rating on the stock notes that no matter how the long-term model plays out, they believe there could be a good trading opportunity around the strong summer season. Firm expects ENOC to report strong results starting in June of each year due to additional capacity ramping in the PJM territory and increased energy payments from outages. If they are correct, we could see slightly stronger results in Q2 (from a one month increase in June) and significantly stronger results in Q3. Believes this strong seasonality could provide a good trading opportunity if the market reacts to these positive Q/Q trends.

Notablecalls: The stock is way down from around $50 in just 2 months. It's going to bounce today.

Actionable Trading Call!

Dts Inc (NASDAQ:DTSI): Surprising channel checks - Deutsche Bank

- Deutsche Bank is out with a positive call on Dts Inc (NASDAQ:DTSI) saying that following 350 store retail check yesterday, they are optimistic Blu-ray can have a near-term positive impact on DTS in the 1H08 as pent-up demand appears to have accelerated Blu-ray player sales over the last two weeks. Firm reiterates their Buy rating as DTS' surround sound technology is mandatory on all Blu-ray players, suggesting an addressable market of $150m+ in revenue (vs. $50m today) and peak EPS of $2.00-$4.00 per share.

DB notes they were surprised to discover that 43% of Blu-ray players in stores are sold out. There has been an increase in demand over the last two weeks. This suggests that DTS is likely to experience the inflection point in the Blu-ray cycle earlier than the firm thought, possibly 2Q08. This faster adoption could drive an additional $0.05- $0.10 EPS to their $0.73 pro forma EPS forecast for 2008.

DTS' strong secular drivers create a stock with the potential to double over the next several years as the Blu-ray cycle develops. DB's $30 target is based on their DCF and embeds 3% terminal growth and a 15% WACC. Over the long-term, they believe a $40+ stock is possible based on peak earnings of $4.00 per share.

Notablecalls: DTSI's a mover and I think this DB call is enough to create nice buy interest in the stock today.

Early morning tidbits:

It's fairly quiet out there this AM with Salesforce.com (NYSE:CRM) or BrutForce.com as it's now called following great results stealing most of the attention.

JP Morgan (NYSE:JPM) is seeing its ests slashed by GSCO, MLCO and Lehman following investor day yesterday.

NC

Wednesday, February 27, 2008

Marathon Oil Corp (NYSE:MRO): Market is significantly underestimating MRO - Citigroup

- Citigroup is out very positive on Marathon Oil Corp (NYSE:MRO) saying they believe the equity market is significantly underestimating the earnings impact of imminent growth in oil and gas production - and in particular, the nuances of MRO's tax position in Norway that should become evident in 2H08.

The kicker is the pending start-up of the Alvheim project in Norway, scheduled for 2Q08 that is the key driver expected to lift oil and gas production by around 16% in 2008 alone (17% inc oil sands), and skew the production mix towards a greater mix of oil.

MRO retains over $1.5bn of legacy tax losses that will fully be fully recovered when production commences. Put simply, early years production from Alvheim – onstream 2Q08 - will have no regional tax and reasonably adds >$1bn to earnings in 2009

Firm is raising their earnings estimates by 5% and 10% respectively in 2008/9 to reflect this impact – but with a conservative oil price deck and higher oil leverage the risks to ‘street’ expectations lies on the upside.

Reits Buy and $82 tgt saying they view MRO as one of the most attractive of the US oil majors for 2008.

Notablecalls: This enough to run the stock today? Yeah, why not.

Tuesday, February 26, 2008

IBM (NYSE:IBM): Benefits of a market savvy management team

Man, the management at IBM (NYSE:IBM) sure is market savvy.

Why do I say this?

Well, they picked the best day for a profit warning.

Huh? Didn't they just up their 2008 EPS guidance?

Yeah, but given they now have $15 billion earmarked for buybacks, this alone should benefit EPS by $0.65.

Yet, IBM upped their 2008 EPS by $0.05.


So there you have it. IBM is looking like a hero for saving the day (indexes ticking green). Benefits of a market savvy management team.


NC

Apple (NASDAQ:AAPL): Piper Jaffray also positive this AM

- Piper Jaffray's Gene Muster is also out positive on Apple (NASDAQ:AAPL) this morning noting that while it is way too early to make a definitive call on March qtr iPod units, they have analyzed the first month of NPD data (Jan.) for the quarter and found that it suggests iPod units of 9.5m-10.3m.

Street consensus for March qtr iPods is 10.8m, representing a 2% y/y increase;the midpoint of the 9.5m-10.3m range suggests a 6% y/y decline.

Firm sees this data point as a slight positive, given recent Street chatter of a very weak iPod number for the qtr, and notes that the monthly contribution they have factored in for Feb. & March may be prove to conservative given the iPod shuffle price cut on 2/19, leading to a more back-end-loaded qtr for iPod units.

Reits Outperform, Alpha List status and $250 tgt.

Notablecalls: So, now we have 2 pos/supportive calls on AAPL this morning. My conviction regarding the n-t bounce thesis grows. As I noted below, I think the slowdown in iPod's has been fully priced in here.

Should this be Actionable? In a way, yes.

Apple (NASDAQ:AAPL): Apple is preparing for meaningful product launches - Morgan Stanley

- Morgan Stanley is out positive on Apple (NASDAQ:AAPL) this AM saying they continue to believe new product announcements and margin expansion will drive AAPL shares higher in 2008. In the near-term, unit expectations need to come down as the product line transitions to higher ASP offerings (iPhone, iPod Touch) But, strong Mac shipments and Apple’s ability to leverage favorable component pricing, leave their CY08 above consensus EPS unchanged.

Beyond industry checks, the firm would point to a 34% YoY increase in R&D and 170% YoY increase in Steve Jobs’ airplane expense in the December quarter as signs Apple is preparing for meaningful product launches.

Apple’s 10-Q shows surprising margin leverage outside the US and a comparison to other retail brands confirms that International expansion tends to be a positive influence on revenue growth, operating margins and valuation. In the near-term, they highlight favorable component pricing that will put upward pressure on gross margin.

Notes AAPL shares already trade at firm's 12-month bear case scenario and they like the risk/reward here (12% downside/55% upside to $185 tgt)

Reits Overweight.

Notablecalls: Can't believe I was actually right, calling it a short last Thursday following disappointing data from iSuppli (see archives).

Yet, now I think it's all priced in here @ around $120. I think people are just looking for a reason to buy this stock and MSCO may have given them the reason to do so.

We are going to see a bounce in AAPL in the n-t.

Monday, February 25, 2008

Vornado (NYSE:VNO): $14bln Penn deal failing? - MSCO

- Morgan Stanley is out with a somewhat cautious call on Vornado (NYSE:VNO) that might work as a short in this environment.

The New York Times reported on Saturday that plans for the $14B redevelopment of Penn Station are close to failing due to the softening economy, government financing, and political inertia.

MSCO notes that were plans for the Penn Station redevelopment to fall through, as suggested in
Saturday's New York Times, they might have cause to re-examine their Overweight rating on VNO’s stock. However, the firm believes it is premature to assume that this complex and highly political project will simply be abandoned, given its importance to NYC and the Hudson Yards redevelopment project, not to mention the number of well-connected developers involved.

In a worst case scenario, in which the project were not to happen at all and VNO is somehow unable to obtain approval for other large projects in the area, they estimate a maximum $11 adverse impact on their $94 price target, reflecting the elimination of previous discounted value of work on the site.

This project represents a significant growth opportunity for VNO, given its 50% development interest and the likely significant positive impact the project would have on its existing assets in the Penn Plaza area.

While the possible Penn failure may be mostly in the stock the prolonged political wrangling over this project, along with market skepticism about the New York office market could keep sentiment negative on this stock for some time.

Notablecalls: The article isn't yet circling the trading desks but I think it will. From what I've read on the Penn project (5-7 mln sqr. ft.), it's one of the most important VNO has.

MSCO's call (while a defense) is cautious enough to create significant pressure in VNO in the n-t.

Citigroup (NYSE:C): Estimates cut big at Opco - Actionable?

Oppenheimer is out with a fairly major call saying they believe the next near term issue of focus for financial investors will be actual loan loss exposures, reserves, necessary provisioning, and subsequent earnings power. Firm is cutting their FY2008 and FY2009 estimates on the large cap banks by an average of 29% and 13%, respectively, based upon their updated accelerated loss curve assumptions as well as estimates for 1st quarter write- downs for leveraged loans.

The most drastic cut is aimed at Citigroup (NYSE:C):

- Opco is lowering otheir 2008 estimate to $0.75 from $2.70, although they believe their revised estimates could still prove optimistic. As C's balance sheet is highly constrained from both an inability to sell lower quality assets due to illiquid markets as well as more assets coming back on its balance sheet due to illiquid markets, the firm continues to believe C will explore every option to sell assets. They continue to believe C will need to sell up to $100 billion in assets. They also continue to argue that under duress, C will likely be forced to sell what it can and not what it should. C will likely only be able to sell its better earning assets for any type of positive return. This, on top of the above mentioned earnings headwinds, will create an intensely challenging earnings year for the company.

Firm believes C shares could fall to levels during the last credit cycle of 1990/1991 or to .7X a share, or below $16 per share, or 36% below current levels. Note, they estimate tangible book value at just over $10 per share.

As they argue in our larger companion piece also published today, firm believes loss rate acceleration is currently grossly underestimated by consensus estimates. Reits Underperform on C.

Notablecalls: The only question is - is it Actionable?

Under "normal" circumstances I would be calling it an outright short. But now there's this ABK situation that complicates things. If we have positive deal news from ABK this morning, all the major banks will go up big time.

So, this one does not come w/o risk.

Friday, February 22, 2008

Discover Financial Services (NYSE:DFS): Solid call from MSCO

It's fairly quiet out there this AM. Think the biggest call seems to be Morgan Stanley's upgrade on Discover Financial Services (NYSE:DFS):

- They are upgrading DFS to Overweight from Underweight as they think it will beat consensus estimates in 2008, thanks to more prudent underwriting (lower credit losses), more leverage in the net interest margin to Fed rate cuts, and limited vulnerability to gapping spreads in the unsecured funding markets. It now looks like more aggressive peers, such as AXP and COF, may have taken on more credit and funding risk than they should have, and the firm expects those companies to disappoint consensus estimates. They regard COF as exposed to subprime card and auto loans. AXP may be in for further problems as prime mortgage troubles spread through its card portfolio, and it is also heavily reliant on unsecured debt, where spreads are now widening. Longer term, they see value in the DFS spin-off story, which has yet to play through to its conclusion.

Firm's new tgt on DFS is $24 (up from $15).

Notablecalls: Looks like a really solid call from MSCO. I expect the stock to trade above $15 today.

Thursday, February 21, 2008

AbitibiBowater Inc (NYSE:ABH): Actionable Call Alert!

- Citigroup is out with an interesting call on AbitibiBowater Inc (NYSE:ABH) saying they have learned the co, with nearly 50% of North American newsprint capacity, has announced a
$60/tonne price increase to be phased in at $20/month April through June.

If successful, they believe ABH would be comfortably free cash flow positive in the 2Q (net of closure costs). Newsprint prices are $620/tonne in February, up from $560 in October. A $20/tonne increase (to $640) is slated for March. The 2Q increase would result in $700.

Citi's “optimistic” estimates for ABH assume that US newsprint prices range between $655-$665/tonne during the second quarter and end the year at $695. However, the ABH move would get newsprint prices above their year-end projections by mid-year. Could even they be low?

ABH’s CFO and Treasurer will present today afternoon at an investor conference in NY. If the bond market is “correct” (with the April 1st bonds trading today around 85), wouldn’t these gentlemen be grabbing pails to bail water back in Greenville?

Citi notes they actually have the sheer audacity to believe management and do not see the sky falling. Firm's target remains $60. Reits Buy.

Notablecalls: WOW! I said WOW! This is a $16 stock, ladies and gentlemen, meaning Citi's tgt represents almost 400% return. Must say I've never seen this kind of stuff coming out of a tier-1 firm. Maybe only in biotechs.

This call has it all:

- Beaten down stock in a out-of-favor sector.

- Analyst coming out with an unexpected catalyst (price hike)

- Huge target

- Management presenting on the same day (& analyst expecting some positive commentary).

This is just perfect!

I'm calling this one Actionable Trading Call.

Be early & aggressive. Could be a 10% mover today.

Apple (NASDAQ:AAPL): Troubling news from iSuppli (edited at 06:57 AM)

Some troubling news for Apple (NASDAQ:AAPL) and Sandisk (NASDAQ:SNDK) from iSuppli this morning:

"..In an early warning sign of consumer weakness, Apple Inc. has slashed its 2008 NAND order forecast significantly and has informed suppliers that its demand growth will slow in 2008 compared to 2007, according to iSuppli sources. This is expected to have a huge impact on the NAND market..."

Link: http://www.isuppli.com/news/default.asp?id=8805

Notablecalls: Note that most of AAPL's NAND comes from SNDK. Expect to see weakness in both.

NAND weakness most likely stems from iPod's. This is not a complete surprise but the situation looks somewhat more troubling than I previously thought.

PS (edit): Forget what I said about shorting AAPL/SNDK. Given RIMM's guidance, CSCO upgrade from Citi and GRMN upgrade from Baird, just fugghedaboutit!

Wednesday, February 20, 2008

Alexion Pharma (NASDAQ:ALXN): Possible bounce play?

Dan from Shark Biotech (www.sharkbiotech.com) shot me some interesting thoughts on Alexion Pharma (NASDAQ:ALXN) this morning:

Another stock that is complete free fall is ALXN which has dropped by 17 points since they reported earnings last week. ALXN sells a drug called Soliris which is the only drug approved to treat PNH a rare blood disorder that causes the destruction of red blood cells.

The stock fell despite the fact the company reported sales of Soliris which beat estimates and increased guidance for 2008. What killed the stock was a downgrade from Wachovia on the assumption that sales would slow in 2009 as the company fully penetrates the PNH market.

Whats important to note that other than Germany the company has really not made any inroads in to the European market. In fact the company just recently launched the drug in the UK. In Asia as well the drug has not yet launched and will probably not do so for at least another 18 months. So although here in the US the drug the market will fully penetrated by the end of this year there is still a lot of worldwide growth to come.

Another factor to consider is the company's pipeline where they are studying Soliris in a number of new indications such as myasthenia gravis and multifocal motor neuropathy. A new indication for the drug would obviously open up a whole new market for which current estimates have not yet factored in .

Although this is not the best market for catching falling knives I am going to start a position in ALXN here at 58 . If it falls more I will consider adding.

NutriSystem (NASDAQ:NTRI): Your daily falling knife

Comments on NutriSystem (NASDAQ:NTRI) following earnings:

- Broadpoint is downgrading their rating to Neutral from Buy. Firm notes having a Buy rating on this stock has been much like havinga javelin through their head: it feels even worse than it looks. Time to pull the javelin outand put this call in the "lessons learned" folder. Firm expects estimates to come down again during the year and thus does not consider NTRI shares attractive at any price greater than $15.

- Oppenheimer notes that although NTRI's 4Q07 results were in-line with consensus (excl. lower than expected tax rate), 1Q08 and 2008 guidance are significantly below expectations. New customer growth for 1Q08 so far remains negative. FY2008 revenue and EBITDA is expected to contract 7.6% and 31.8%, respectively. Firm continues to foresee a very challenging 2008 for NTRI with substantial revenues and earnings risks.

They are reducing 1Q08 estimate to $0.28 from $0.88, 2008 estimate to $2.06 from $2.89, and FY09 estimate to $2.50 from $3.43. Specifically, they estimate A&M expense to increase by 40%+ in 1Q08. There is no change to Perform rating.

- Citigroup is more bullish on NTRI, sticking to their Buy rating while lowering tgt to $29 from $38 saying that discussed in their Feb. 7th preview note, they expected mgmt to provide conservative guidance.

Mgmt mentioned trends through January were weak due in part to the soft economy. Given its $300 price point (for a 30 day supply), sales may be impacted to some extent by a weak economy. Encouragingly, they do not believe the co lost market share given weakness at other diet cos.

NTRI faces very tough compares in 1H08. Therefore, if we see continued stabilized trends in 1H08, NTRI should experience decent growth in 2H08. Shares still appear attractive at 8x '08 EPS.

Notablecalls: Even with ests slashed way below previous levels, the shares still trade below 10x 2008 EPS. There's a close to 70% short interest in the name. It's down big over the past 6 months and down an additional 25% in pre-mkt. The shorts have won. No question about it.

I think they will be ringing the register on at least some of the gains they are now sitting on. I know I would.

Hence, the stock's a buy for a bounce around the $17 level. Not because the business is recovering but rather because of the shorts. Tight leash as always.

Your daily falling knife.

PS: Broadpoint's dg sure feels like capitulation.

PPS: I bought tiny CROX in pre-mkt despite the controversy around the inventory (up yet again) It's just so..cheap & overshorted.

Tuesday, February 19, 2008

RUMOUR MILL: Suntech (NYSE:STP)

Hearing Street chatter Suntech (NYSE:STP) guidance tomorrow morning will be disappointing on the GM side as the co has been struggling to get poly supply deals done, forcing it to buy from MEMC & Hemlock on the spot mkt.

NCN Solar comments:

Just a little comment on that, they will likely buy less than 10% of supply on spot but they likely won't go for more supply considering spot rates are over $400. About 50% is long term 40% is sort of in between, sort of deals they make, meaning not as good as long term, but much below spot.

Regardless, can't expect a great STP report, tho long term, you can't overly punish them for near term poly price issues, meaning there will be time to buy this one back its a supply issue, not demand, and I'm looking to buy FSLR tomorrow, if the STP report is weak in fact, and the group trades lower.

Suntech (NYSE:STP): Beat & Raise?

- Cowen is out positive on Suntech (NYSE:STP) saying they believe the co is poised for a beat-and-raise quarter. Guidance for 2008 shipments ought to be revised up. STP is targeting YE capacity of 1GW, so H2 upside looks do-able with likely incremental silicon supply. STP has an aggressive/diversified silicon procurement strategy. High spot prices seem offsettable by rising conversion efficiency and scale. New Pluto technology and product diversification should expand the P/E. Sees 50%+ upside vs. the market in 12 months and reiterates Outperform rating.

Thinks management may raise 2008 guidance.

They believe STP shares do not yet command full value for its technology and product diversification efforts. As Pluto lines ramp, higher conversion efficiency should aid GM. And, other new products like thin-film for BIPV and Andalay modules further differentiate it from competitors.

Notablecalls: Note that Lehman is out on STP this AM cutting their tgt to $75 from $100 while keeping their Overweight rating.

The Cowen call strucks me as somewhat surprising as I happen to know that Suntech's management sounded a bit cautious couple of weeks ago when they spoke to a group of investors. Of course, no guidance was provided (reg fd). Yet, now we have Cowen out saying they feel STP is going to have a beat & raise qtr when they report tomorrow morning.

The cautious tone has attracted some short-sellers over the past weeks, so I would not be surprised to see some short covering on heels of Cowen's "beat & raise" call. Think the short community has too painful memories from the FSLR short last week.

Anyway, not making a call here but one to watch.

Onyx Pharma (NASDAQ:ONXX): Strong bounce candidate below $40

We have couple of firms commenting on Onyx Pharma (NASDAQ:ONXX) after partner Bayer announced that Nexavar's Phase III trial in lung cancer was stopped early by the trial's data safety monitoring board because of futility.

- Morgan Stanley maintains their Overweight rating and $65 tgt saying the failed ESCAPE trial for Nexavar in non-small cell lung cancer (NSCLC) is a disappointment, and they expect the stock to be down ~5-10% on the news. However, their numbers, price target, and rating are based upon their thesis in liver cancer, particularly ex-US, and they continue to believe the Street underestimates this $500 million + opportunity. MSCO making no changes to numbers or price target.

- Cowen notes they did not have any estimates for lung cancer in their model. However, they believe that some investors and analysts did. Moreover, even for those who didn't have explicit lung cancer estimates, the option value of lung cancer likely supported several points in Onyx's stock price. Firm expects Onyx will be weak today no matter what Q4:07 Nexavar sales number is reported later this morning.

If ONXX is significantly weak today they believe it would provide a buying opportunity. Maintains Outperform.

Notablecalls: I see some pre-market trades crossing around 15-20% below Friday's close. Make sure you're involved on the long side as expectations regarding the lung cancer trial were very modest. I think MSCO's right with their 5-10% downside estimate. That would equal to a $40+ stock price, not the $35-38 level we are seeing in the pre mkt. I suspect we're dealing with some daytraders who are simply shorting the thing down 20% without any real knowledge of the situation.

Oh and btw, ONXX is a monster bouncer. Would not be surprised to see it trade over $40 level today.

Sunday, February 17, 2008

NCN Solar: The current state of things

Last week I asked NCN Solar, a trader closely following & trading the Solar space give us an overview of the current state of the things. I talk to NCN Solar almost every morning going over the most important developments - a great help to undestanding the rapidly changing sector.

I also regularly paste his best comments to other Notable Calls Network (NCN) members.


NCN Solar:

I put some thoughts together more to educate you as to what is happening, and perhaps will make it easier to capitalize on coming news in 2008. It will continue to be choppy and unpredictable, so its best to just be prepared for what may happen and to know how to react.

There seems to be more private equity money going into alternative energy than in any other sector. The high oil prices of the last few years as well as climate concerns, has led to a quest to reach grid parity with electric rates. Most of the ways to play the growth in the US markets involve stocks in the Solar sector. There are 2 well known technologies: Thin Film which includes First Solar (NASDAQ:FSLR), Energy Conversion Devices (NASDAQ:ENER), and many exciting private companies and Silicon which is led by SunPower Corp (NASDAQ:SPWR), Suntech Power (NYSE:STP) and many others.

Let us take a closer look at both these groups. FSLR is the clear cost leader. They developed Thin Film CDTE technology which doesn't require the currently expensive polysilicon, and is a quick production process which FSLR has successfully copied at their other facilities. There are certain geographies, such as areas of Germany, where no other product can come close to comparing. As they increase their conversion efficiency to 12% of the sunlight to power, and continue to increase production and yields, they appear well in the lead towards grid parity, at a point which this growing market expands to incredible levels. There are a number of private companies, NanoSolar, Miasole etc. as well as ASTI and DSTI which are working on Thin Film CIGS technology in a well financed drive to reach what FSLR has accomplished. There are various challenges in scaling this technology, and its certainly hard to know exactly how close these companies have come. The Thin Film amorphous technology, is a bit difficult to understand, because the conversion efficiency achieved so far, does not seem high enough to compete.

As we enter 2008, no one comes close to FSLR in terms of cost per watt. So why is there strong interest in anyone else? In the residential market, it does not appear that FSLR will be a player, and I’m not sure they are even suitable for that. Because FSLR has lower efficiency, they require more panels, which means the amount of roof space, or cost of land, can tilt the economics. There are also various geographies, where perhaps the amount of sunlight or heat, can work better for a silicon company. As we stand right now, the costs for silicon panel companies are much higher, but they are greatly influenced by the inflated level of polysilicon prices. The current poly demand dwarfs the supply. This affects the companies in different ways, and its worth looking at which solar stocks have most of their polysilicon at contract rates, and which need to purchase their required poly at spot prices. At some point, the additional supply from China will come online, and one would expect the prices to drop significantly. A company like WFR which benefits from selling polysilicon in the market, will have to deal with the lower prices in the future, though at this time, they are doing very well. Once these prices do come down, the buyers of polysilicon, STP SPWR etc. will see their costs dropping and can become more competitive with FSLR in more locations, and can start the move towards grid parity. At this point SPWR is a technology leader with their high efficiencies, and tracking systems, and STP is a leader helped by their low cost operation and low taxes. We will see if anyone else can make the leap to the top tier.

The important thing to understand is that what is good for one solar company may not mean much for another. We recently saw FSLR blow away estimates for the quarter and guide higher. This may not mean that the silicon players will have a good quarter. But it does show what can be achieved, when your costs are low, and when you run the operation smoothly. A future drop in polysilicon prices would be a big help for a polysilicon company that buys at spot prices, but may not mean as much for a silicon company that has a great supply, and would probably be negative for FSLR because other companies will become more competitive in some markets.

What I look for in 2008, is that we will see the winners and the losers start to emerge. The same way that many tech companies did not emerge from the internet boom, many wont succeed in solar. But the ones who will, meaning the ones that achieve grid parity, or assist companies in achieving, will be continued winners. We should begin to see more poly supply come on line before the end of the year, and a drop in poly prices will help the industry. At a certain point, the silicon players may decide they would rather not sell a panel even if there is demand, because they don’t want to pay up for poly. But that would lead to this coming drop in prices. Utility solar deals will be big news this year. FSLR has suggested that there will be multiple pilot projects for utility solar deals in the United States and a number of companies will be in the race for utility deals. This may be helped by the expected extension of solar tax credits which should take place before the end of the year. There is bypartisan support for these credits, and once the politics get played out, it seems clear that the bill will get passed. We may hear more about other solar technologies. EMKR is a player in CPV (Concentrated PhotoVoltaic) which has high conversion efficiency, and concentrates the sunlight on to a cell. There is also strong potential from solar thermal technology. We should also here more about the progress on Nanosolar and other new entrants. There likely will be more ups and downs then we saw in 2007, which was virtually all up. But there should be some big winners once again from some old and perhaps some new names.


Best regards,

NCN Solar

Friday, February 15, 2008

Feedback: Chipotle Mexican Grill (NYSE:CMG)

After I read your post this morning prior to the open, I put in an order for FEB 100 Calls at .25 cents. I picked up 100 contracts around the time the price was 97$ and sold them for 3$ each at 2 p.m. when CMG was over 103$. Thanks for the excellent information. I wish every option expiration day was like this....

J.F.

Notablecalls: Love it. Stuff like this keeps me ticking.